387 related articles for article (PubMed ID: 29547597)
21. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
23. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Keating GM
Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
[TBL] [Abstract][Full Text] [Related]
24. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Badalamenti G; Incorvaia L; Messina C; Musso E; Casarin A; Ricciardi MR; De Luca I; Bazan V; Russo A
Support Care Cancer; 2019 Sep; 27(9):3593-3597. PubMed ID: 30762142
[TBL] [Abstract][Full Text] [Related]
25. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Rugo HS; Aapro MS
Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
[TBL] [Abstract][Full Text] [Related]
26. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Lorusso V; Karthaus M; Aapro M
Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
[TBL] [Abstract][Full Text] [Related]
28. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Loteta B; Paviglianiti A; Naso V; Ferreri A; Moscato T; Console G; Canale FA; Irrera G; Pugliese M; Di Costanzo A; Provenzano PF; Loddo V; Porto G; Cusumano G; Russo L; Meliambro N; Romeo V; Porcino D; Gallo S; Gangemi T; Rossetti AM; Martino M
Support Care Cancer; 2022 Jan; 30(1):585-591. PubMed ID: 34347181
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
[TBL] [Abstract][Full Text] [Related]
30. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
31. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
32. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K; Jahn F; Aapro M
Ann Oncol; 2015 Jun; 26(6):1081-1090. PubMed ID: 25755107
[TBL] [Abstract][Full Text] [Related]
33. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
34. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
[TBL] [Abstract][Full Text] [Related]
35. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract][Full Text] [Related]
37. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
Giuliani J; Bonetti A
Curr Opin Oncol; 2020 Jul; 32(4):269-273. PubMed ID: 32541312
[TBL] [Abstract][Full Text] [Related]
39. Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Roeland E; Aapro MS; Schwartzberg LS
Clin Adv Hematol Oncol; 2015 Oct; 13(10 Suppl 10):1-14. PubMed ID: 26859507
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Nilsson J; Piovesana V; Turini M; Lezzi C; Eriksson J; Aapro M
Support Care Cancer; 2022 Nov; 30(11):9307-9315. PubMed ID: 36074186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
